Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress
Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress
默沙東宣佈將在2024年聯合歐洲胃腸病學周大會上展示Tulisokibart(Mk-7240)在潰瘍性結腸炎和克羅恩病中的長期療效和安全性數據。
Merck Announced That New Data Highlighting The Long-term Efficacy And Safety Of Tulisokibart (MK-7240) In Ulcerative Colitis And Crohn's Disease Will Be Presented At The United European Gastroenterology Week 2024 Congress
默沙東宣佈將在2024年聯合歐洲胃腸病學周大會上展示Tulisokibart(Mk-7240)在潰瘍性結腸炎和克羅恩病中的長期療效和安全性數據。